C.H. Barrios

3.3k total citations
38 papers, 585 citations indexed

About

C.H. Barrios is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C.H. Barrios has authored 38 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 19 papers in Cancer Research. Recurrent topics in C.H. Barrios's work include Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (15 papers) and Advanced Breast Cancer Therapies (14 papers). C.H. Barrios is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (15 papers) and Advanced Breast Cancer Therapies (14 papers). C.H. Barrios collaborates with scholars based in Brazil, United States and Spain. C.H. Barrios's co-authors include Monika Patre, Andreas Schneeweiß, Peter Ellis, Mark L. McCleland, Luciana Molinero, Filippo de Marinis, Niels Reinmuth, Enriqueta Felip, Ida Enquist and Masahiro Morise and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

C.H. Barrios

35 papers receiving 578 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C.H. Barrios Brazil	11	502	302	176	89	78	38	585
Erik J. Blok Netherlands	13	342 0.7×	180 0.6×	269 1.5×	97 1.1×	64 0.8×	19	548
Ekaterina Trishkina Russia	7	426 0.8×	335 1.1×	196 1.1×	62 0.7×	104 1.3×	11	563
M-J. Ahn South Korea	14	517 1.0×	394 1.3×	93 0.5×	118 1.3×	105 1.3×	68	622
Elaine Shum United States	13	388 0.8×	348 1.2×	69 0.4×	176 2.0×	78 1.0×	52	586
Monica Milano Italy	10	311 0.6×	138 0.5×	176 1.0×	134 1.5×	60 0.8×	22	489
Antonio Russo Italy	8	296 0.6×	270 0.9×	155 0.9×	114 1.3×	36 0.5×	14	428
Ulla Wilking Sweden	7	460 0.9×	171 0.6×	330 1.9×	95 1.1×	28 0.4×	20	608
Rinat Galiulin United States	6	370 0.7×	388 1.3×	110 0.6×	135 1.5×	37 0.5×	7	556
Julio A. Peguero United States	12	368 0.7×	241 0.8×	78 0.4×	133 1.5×	92 1.2×	49	517
Eleonora Restuccia Switzerland	15	524 1.0×	212 0.7×	154 0.9×	64 0.7×	78 1.0×	48	626

Countries citing papers authored by C.H. Barrios

Since Specialization

Citations

This map shows the geographic impact of C.H. Barrios's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.H. Barrios with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.H. Barrios more than expected).

Fields of papers citing papers by C.H. Barrios

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.H. Barrios. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.H. Barrios. The network helps show where C.H. Barrios may publish in the future.

Co-authorship network of co-authors of C.H. Barrios

This figure shows the co-authorship network connecting the top 25 collaborators of C.H. Barrios. A scholar is included among the top collaborators of C.H. Barrios based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.H. Barrios. C.H. Barrios is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mitsuyuki, Milene Corso, et al.. (2025). Disparities in cancer clinical trials among low‐ and middle‐income countries: A 20‐year analysis. Cancer. 131(21). e70067–e70067.

Barrios, C.H., Nadia Harbeck, Shigehira Saji, et al.. (2023). LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC). ESMO Open. 8(1). 101571–101571. 13 indexed citations

Dziadziuszko, Rafał, Solange Peters, Shirish M. Gadgeel, et al.. (2021). 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C. Annals of Oncology. 32. S950–S951. 10 indexed citations

Miles, D.W., Joseph Gligorov, Fabrice André, et al.. (2020). LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. 31. S1147–S1148. 74 indexed citations

Turner, Nicholas C., Rebecca Dent, Joyce O’Shaughnessy, et al.. (2020). 283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial. Annals of Oncology. 31. S354–S355. 10 indexed citations

Saji, Shigehira, EA Mittendorf, Nadia Harbeck, et al.. (2020). 3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC). Annals of Oncology. 31. S1243–S1243. 2 indexed citations

Rugo, H. S., Sherene Loi, Sylvia Adams, et al.. (2019). Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Annals of Oncology. 30. v858–v859. 84 indexed citations

Lambertini, Matteo, Christine Campbell, José Bines, et al.. (2017). Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06). Annals of Oncology. 28. v47–v47. 1 indexed citations

Reinert, Tomás, Márcio Debiasi, José Bines, & C.H. Barrios. (2017). Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer. Breast Cancer Research and Treatment. 168(2). 457–465. 3 indexed citations

10.

Montemurro, Filippo, Peter Ellis, Suzette Delaloge, et al.. (2017). Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study. Cancer Research. 77(4_Supplement). P1–12. 19 indexed citations

11.

Barlési, Fabrice, K. Park, Fortunato Ciardiello, et al.. (2016). Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Annals of Oncology. 27. vi581–vi581. 56 indexed citations

12.

Pivot, Xavier, C. J. Poole, Miguel Martín, et al.. (2016). An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies. Annals of Oncology. 27. vi63–vi63. 1 indexed citations

13.

Jänne, Pasi A., Ian C. P. Smith, Gael McWalter, et al.. (2015). Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. British Journal of Cancer. 113(2). 199–203. 59 indexed citations

14.

Piccart, Martine, Evandro de Azambuja, Serena Di Cosimo, et al.. (2013). Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06). Cancer Research. 73(24_Supplement). S1–1. 15 indexed citations

15.

André, Fabrice, Patrick Neven, Antonino Musolino, et al.. (2013). Abstract OT2-6-04: Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study. Cancer Research. 73(24_Supplement). OT2–6. 2 indexed citations

16.

Lluch, Aňa, Manuel Ruíz‐Borrego, C.H. Barrios, et al.. (2012). 422 Final Safety Data From a Randomised Phase III Trial (CIBOMA/2004-01_GEICAM/2003-11) Assessing Adjuvant Capecitabine Maintenance Therapy After Standard Chemotherapy for Triple-negative Early Breast Cancer. a Study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Español De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer. 48. S169–S170. 3 indexed citations

17.

Steger, G.G., et al.. (2011). P307 Capecitabine (C) for triple-negative early breast cance (TNBC): Review of available clinical data. The Breast. 20. S75–S75. 1 indexed citations

18.

Lluch, Aňa, Henry Gómez, Manuel Ruíz‐Borrego, et al.. (2010). Abstract P5-10-15: First Safety Data from a Randomised Phase III (CIBOMA 2004- 01/GEICAM 2003-11) Trial Assessing Adjuvant Capecitabine Maintenance Therapy after Standard Chemotherapy for Triple-Negative Early Breast Cancer. Cancer Research. 70(24_Supplement). P5–10. 9 indexed citations

19.

Lluch, Aňa, C.H. Barrios, José Bines, et al.. (2009). 5150 CIBOMA/2004–01: a randomised phase III trial assessing adjuvant capecitabine (X) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC). European Journal of Cancer Supplements. 7(2). 305–305. 3 indexed citations

20.

Bell, R., C.H. Barrios, Р. Ш. Хасанов, et al.. (2007). 2120 POSTER Retreatment with trastuzumab after relapse following adjuvant trastuzumab treatment (the RHEA trial): preliminary efficacy data. European Journal of Cancer Supplements. 5(4). 220–220. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact